Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2024Clinical and Molecular HepatologyOpen Access

Currently, 38% of all adults and 7-14% of children and adolescents have MASLD, with prevalence projected to increase to more than 55% by 2040.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

With global rates of obesity and type 2 diabetes rising, this review discusses MASLD epidemiology, related risk factors, and outcomes to highlight the growing disease burden.

Design

Review

Authors

ZYZobair M. YounossiMKMarkos KalligerosLHLinda Henry

Discussion

Loading...

Member takes

Overview

Rising MASLD prevalence flags CVD as leading mortality driver; leaves open optimal global management strategies.

Structured PICO

P
Population
Populations globally with or at risk for metabolic dysfunction-associated steatotic liver disease (MASLD)

MASLD is a growing global epidemic with cardiovascular disease as its leading cause of mortality, necessitating further global initiatives for management.

Cite This Study

Younossi et al. (2024) studied this question.

synapsesocial.com/papers/69d7228fef370a38abf50dcfhttps://doi.org/10.3350/cmh.2024.0431
View Full Paper
Ask AI
Bookmark
Share